CHA2DS2-VASc评分在生物瓣主动脉瓣置换术后卒中预测中的表现
该回顾性多中心研究纳入714例生物瓣主动脉瓣置换患者,评估CHA2DS2-VASc评分对术后卒中/短暂性脑缺血发作的预测价值。中位随访4.8年,评分5-9分患者卒中/TIA风险显著高于低分患者(HR 4.75,95%CI 1.09-20.6,P=0.037)。作者认为该评分有助于识别卒中及大出血高风险患者。
要点
- CHA2DS2-VASc评分5-9分患者卒中/TIA风险显著高于0-1分患者(HR 4.75)。
- 1年卒中/TIA发生率:低分2.6%、高分4.8%、极高分组10.7%。
- 5年大出血发生率:低分0%、高分5.4%、极高分组8.7%。
核心结论
- CHA2DS2-VASc评分是识别生物瓣主动脉瓣置换术后卒中及大出血高风险患者的有价值工具,作者认为对这类患者应采用替代策略预防晚期神经并发症。
研究设计与样本
- 回顾性研究,纳入4所大学医院714例接受孤立性生物瓣主动脉瓣置换术的患者,数据从病历回顾收集并由独立方监测。
主要发现
- 中位随访4.8年,平均CHA2DS2-VASc评分为4.1±1.6。
- 低分(0-1分)、高分(2-4分)和极高分(5-9分)患者分别为39例(5.5%)、400例(56.0%)和262例(38.5%)。
- 1年卒中或TIA发生率:低分2.6%、高分4.8%、极高分组10.7%;5年分别为5.2%、14.0%、21.9%;10年分别为5.2%、20.7%、37.9%。
- 1年大出血发生率:低分0%、高分1.8%、极高分组2.7%;5年分别为0%、5.4%、8.7%;10年分别为0%、9.0%、27.1%。
- 竞争风险分析显示,CHA2DS2-VASc评分5-9分患者较低风险患者卒中或TIA风险显著增加(HR 4.75,95%CI 1.09-20.6,P=0.037),与术前或院内新发房颤无关。
临床怎么用
- 作者认为CHA2DS2-VASc评分可用于识别生物瓣主动脉瓣置换术后卒中及大出血高风险患者,并认为对这类患者应采用替代策略预防晚期神经并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Stroke is a frequent complication occurring early and late after surgical aortic valve replacement. There is an unmet clinical need for simple tools to assess postoperative stroke risk. We sought to assess the predictive performance of Congestive heart failure; Hypertension; Age ≥75 (doubled); Diabetes mellitus; prior Stroke, transient ischemic attack or thromboembolism (doubled); Vascular disease; Age 65 to 74; Sex category (female) (CHA2DS2-VASc) score in patients undergoing surgical aortic valve replacement with a bioprosthesis. METHODS: Seven hundred fourteen patients undergoing isolated surgical aortic valve replacement with a bioprosthesis at 4 university hospitals were included. Data were collected retrospectively from patient records and monitored by an independent party. RESULTS: Median follow-up time was 4.8 years. Mean CHA2DS2-VASc score was 4.1 ± 1.6. Low (scores, 0-1), high (scores, 2-4), and very high (scores, 5-9) CHA2DS2-VASc scores were observed in 39 (5.5%), 400 (56.0%), and 262 (38.5%) patients, respectively. Incidences of stroke or transient ischemic attack at 1 year were 2.6%, 4.8%, and 10.7%; at 5 years incidences were 5.2%, 14.0%, and 21.9%; and at 10 years incidence were 5.2%, 20.7%, and 37.9% for patients in low, high, and very high scores, respectively. Incidences of major bleeds at 1 year were 0%, 1.8%, and 2.7%; at 5 years incidences were 0%, 5.4%, and 8.7%; and at 10 years incidences were 0%, 9.0%, and 27.1%, respectively. Competing risk analysis showed that patients with CHA2DS2-VASc score of 5 through 9 had a significantly increased risk of stroke or transient ischemic attack (hazard ratio, 4.75; 95% confidence interval, 1.09-20.6; P = .037) irrespective of preoperative or new-onset in-hospital atrial fibrillation compared with low-risk patients. CONCLUSIONS: CHA2DS2-VASc is a valuable tool to identify patients with increased risk of stroke and major bleeding, and for whom alternative strategies for prevention of late neurologic complications should be adopted.
引用
- Kiviniemi T, Lehto J, Nissinen M, et al. Performance of CHA2DS2-VASc score for stroke prediction after surgical aortic valve replacement. J Thorac Cardiovasc Surg. 2018. PMID: 30174132. doi:10.1016/j.jtcvs.2018.06.096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。